143 related articles for article (PubMed ID: 17059374)
1. Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men.
Vandenput L; Labrie F; Mellström D; Swanson C; Knutsson T; Peeker R; Ljunggren O; Orwoll E; Eriksson AL; Damber JE; Ohlsson C
J Bone Miner Res; 2007 Feb; 22(2):220-7. PubMed ID: 17059374
[TBL] [Abstract][Full Text] [Related]
2. Androgen glucuronides analysis by liquid chromatography tandem-mass spectrometry: could it raise new perspectives in the diagnostic field of hormone-dependent malignancies?
Kalogera E; Pistos C; Provatopoulou X; Athanaselis S; Spiliopoulou C; Gounaris A
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Dec; 940():24-34. PubMed ID: 24140653
[TBL] [Abstract][Full Text] [Related]
3. Androgens and glucuronidated androgen metabolites are associated with metabolic risk factors in men.
Vandenput L; Mellström D; Lorentzon M; Swanson C; Karlsson MK; Brandberg J; Lönn L; Orwoll E; Smith U; Labrie F; Ljunggren O; Tivesten A; Ohlsson C
J Clin Endocrinol Metab; 2007 Nov; 92(11):4130-7. PubMed ID: 17711928
[TBL] [Abstract][Full Text] [Related]
4. Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden.
Mellström D; Johnell O; Ljunggren O; Eriksson AL; Lorentzon M; Mallmin H; Holmberg A; Redlund-Johnell I; Orwoll E; Ohlsson C
J Bone Miner Res; 2006 Apr; 21(4):529-35. PubMed ID: 16598372
[TBL] [Abstract][Full Text] [Related]
5. SHBG gene promoter polymorphisms in men are associated with serum sex hormone-binding globulin, androgen and androgen metabolite levels, and hip bone mineral density.
Eriksson AL; Lorentzon M; Mellström D; Vandenput L; Swanson C; Andersson N; Hammond GL; Jakobsson J; Rane A; Orwoll ES; Ljunggren O; Johnell O; Labrie F; Windahl SH; Ohlsson C
J Clin Endocrinol Metab; 2006 Dec; 91(12):5029-37. PubMed ID: 16926255
[TBL] [Abstract][Full Text] [Related]
6. Androgen inactivation and steroid-converting enzyme expression in abdominal adipose tissue in men.
Blouin K; Richard C; Brochu G; Hould FS; Lebel S; Marceau S; Biron S; Luu-The V; Tchernof A
J Endocrinol; 2006 Dec; 191(3):637-49. PubMed ID: 17170221
[TBL] [Abstract][Full Text] [Related]
7. The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17 deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men.
Swanson C; Mellström D; Lorentzon M; Vandenput L; Jakobsson J; Rane A; Karlsson M; Ljunggren O; Smith U; Eriksson AL; Bélanger A; Labrie F; Ohlsson C
J Clin Endocrinol Metab; 2007 Dec; 92(12):4878-82. PubMed ID: 17698910
[TBL] [Abstract][Full Text] [Related]
8. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
[TBL] [Abstract][Full Text] [Related]
9. Radical prostatectomy: influence on serum and urinary androgen levels.
Olsson M; Ekström L; Schulze J; Kjellman A; Akre O; Rane A; Gustafsson O
Prostate; 2010 Feb; 70(2):200-5. PubMed ID: 19760638
[TBL] [Abstract][Full Text] [Related]
10. Partitioning of 5alpha-dihydrotestosterone and 5alpha-androstane-3alpha, 17beta-diol activated pathways for stimulating human prostate cancer LNCaP cell proliferation.
Nunlist EH; Dozmorov I; Tang Y; Cowan R; Centola M; Lin HK
J Steroid Biochem Mol Biol; 2004 Jul; 91(3):157-70. PubMed ID: 15276623
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: a randomized, placebo-controlled trial.
Idan A; Griffiths KA; Harwood DT; Seibel MJ; Turner L; Conway AJ; Handelsman DJ
Ann Intern Med; 2010 Nov; 153(10):621-32. PubMed ID: 21079217
[TBL] [Abstract][Full Text] [Related]
12. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
Yang Q; Titus MA; Fung KM; Lin HK
J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
[TBL] [Abstract][Full Text] [Related]
13. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer.
Titus MA; Schell MJ; Lih FB; Tomer KB; Mohler JL
Clin Cancer Res; 2005 Jul; 11(13):4653-7. PubMed ID: 16000557
[TBL] [Abstract][Full Text] [Related]
14. IGF-I and testosterone levels as predictors of bone mineral density in healthy, community-dwelling men.
Rucker D; Ezzat S; Diamandi A; Khosravi J; Hanley DA
Clin Endocrinol (Oxf); 2004 Apr; 60(4):491-9. PubMed ID: 15049965
[TBL] [Abstract][Full Text] [Related]
15. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
Galvão DA; Spry NA; Taaffe DR; Newton RU; Stanley J; Shannon T; Rowling C; Prince R
BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
[TBL] [Abstract][Full Text] [Related]
16. Prolactin influences upon androgen action in male accessory sex organs.
Thomas JA; Keenan EJ
Adv Sex Horm Res; 1976; 2():425-70. PubMed ID: 189591
[TBL] [Abstract][Full Text] [Related]
17. Reduced circulating androgen bioactivity in patients with prostate cancer.
Raivio T; Santti H; Schatzl G; Gsur A; Haidinger G; Palvimo JJ; Jänne OA; Madersbacher S
Prostate; 2003 May; 55(3):194-8. PubMed ID: 12692785
[TBL] [Abstract][Full Text] [Related]
18. Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer.
Morabito N; Gaudio A; Lasco A; Catalano A; Atteritano M; Trifiletti A; Anastasi G; Melloni D; Frisina N
J Bone Miner Res; 2004 Nov; 19(11):1766-70. PubMed ID: 15476575
[TBL] [Abstract][Full Text] [Related]
19. Serum androgen bioactivity during 5alpha-dihydrotestosterone treatment in elderly men.
Raivio T; Tapanainen JS; Kunelius P; Jänne OA
J Androl; 2002; 23(6):919-21. PubMed ID: 12399539
[TBL] [Abstract][Full Text] [Related]
20. Reproducibility of serum sex steroid assays in men by RIA and mass spectrometry.
Hsing AW; Stanczyk FZ; Bélanger A; Schroeder P; Chang L; Falk RT; Fears TR
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1004-8. PubMed ID: 17507629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
